Actively Recruiting
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Led by Pierre Fabre Pharma GmbH · Updated on 2021-01-19
750
Participants Needed
59
Research Sites
410 weeks
Total Duration
On this page
Sponsors
P
Pierre Fabre Pharma GmbH
Lead Sponsor
P
Pierre Fabre Pharma Austria
Collaborating Sponsor
AI-Summary
What this Trial Is About
BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or metastatic BRAF(Rapidly Accelerated Fibrosarcoma isoform B)-V600-mutant malignant melanoma after commercial availability of these two products in Germany, Austria and Switzerland. The study focusses on the documentation of the first and second line setting (i.e. after one line of prior checkpoint inhibition) by documenting patients treated according to the SmPC (Summary of Product Characteristics).
CONDITIONS
Official Title
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent for study documentation and data processing
- Male or female patients aged 18 years or older
- Decision to treat with encorafenib plus binimetinib made before study inclusion
- Treatment with encorafenib plus binimetinib started within 6 months prior to consent or planned soon
- Unresectable advanced or metastatic melanoma with BRAF V600 mutation
- Treatment-naive or after one prior checkpoint inhibitor line in advanced/metastatic setting
You will not qualify if you...
- Previous treatment with BRAF and/or MEK inhibitors except adjuvant therapy ended more than 6 months before study treatment
- More than one prior checkpoint inhibitor treatment line in advanced/metastatic setting
- Any previous chemotherapy for melanoma
- Any contraindication to encorafenib-binimetinib treatment per prescribing information
- Current or planned participation in an interventional clinical trial
- Current or planned systemic treatment for tumors other than melanoma
- Prisoners or involuntarily incarcerated persons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 59 locations
1
11
Graz, Austria
Actively Recruiting
2
13
Innsbruck, Austria
Actively Recruiting
3
14
Klagenfurt, Austria
Actively Recruiting
4
10
Linz, Austria
Actively Recruiting
5
3
Linz, Austria
Actively Recruiting
6
12
Salzburg, Austria
Actively Recruiting
7
22
Vienna, Austria
Actively Recruiting
8
53
Vienna, Austria
Actively Recruiting
9
23
Wiener Neustadt, Austria
Actively Recruiting
10
45
Ahaus, Germany
Actively Recruiting
11
8
Aschaffenburg, Germany
Actively Recruiting
12
56
Augsburg, Germany
Actively Recruiting
13
51
Berlin, Germany
Actively Recruiting
14
27
Bremerhaven, Germany
Actively Recruiting
15
1
Buxtehude, Germany
Actively Recruiting
16
43
Chemnitz, Germany
Actively Recruiting
17
34
Donauwörth, Germany
Actively Recruiting
18
49
Dresden, Germany
Actively Recruiting
19
47
Duisburg, Germany
Actively Recruiting
20
40
Erfurt, Germany
Actively Recruiting
21
20
Essen, Germany
Actively Recruiting
22
9
Gera, Germany
Actively Recruiting
23
28
Giessen, Germany
Actively Recruiting
24
42
Goslar, Germany
Actively Recruiting
25
59
Göttingen, Germany
Actively Recruiting
26
19
Hamburg, Germany
Actively Recruiting
27
21
Hanover, Germany
Actively Recruiting
28
2
Heidelberg, Germany
Actively Recruiting
29
33
Karlsruhe, Germany
Actively Recruiting
30
39
Kiel, Germany
Actively Recruiting
31
29
Landshut, Germany
Actively Recruiting
32
44
Leipzig, Germany
Actively Recruiting
33
30
Ludwigshafen, Germany
Actively Recruiting
34
4
Lübeck, Germany
Actively Recruiting
35
46
Magdeburg, Germany
Actively Recruiting
36
15
Mainz, Germany
Actively Recruiting
37
5
Mannheim, Germany
Actively Recruiting
38
57
Marburg, Germany
Actively Recruiting
39
6
Minden, Germany
Actively Recruiting
40
31
München, Germany
Actively Recruiting
41
7
München, Germany
Actively Recruiting
42
16
Münster, Germany
Actively Recruiting
43
35
Münster, Germany
Actively Recruiting
44
18
Nuremberg, Germany
Actively Recruiting
45
50
Regensburg, Germany
Actively Recruiting
46
41
Schorndorf, Germany
Actively Recruiting
47
17
Schwerin, Germany
Actively Recruiting
48
48
Stolberg, Germany
Actively Recruiting
49
55
Trier, Germany
Actively Recruiting
50
54
Tübingen, Germany
Actively Recruiting
51
32
Zwickau, Germany
Actively Recruiting
52
52
Bellinzona, Canton Ticino, Switzerland, 6500
Actively Recruiting
53
38
Aarau, Switzerland
Actively Recruiting
54
37
Bern, Switzerland, 3010
Actively Recruiting
55
24
Chur, Switzerland
Actively Recruiting
56
36
Lausanne, Switzerland
Actively Recruiting
57
58
Lucerne, Switzerland, 6000
Actively Recruiting
58
26
Winterthur, Switzerland
Actively Recruiting
59
25
Zurich, Switzerland
Actively Recruiting
Research Team
C
Christian A Rosé, MD
CONTACT
A
Andrea Schmidt, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here